Xilio Therapeutics, Inc. (XLO)

Market Cap	42.37M
Revenue (ttm)	31.80M
Net Income (ttm)	-58.49M
Shares Out	52.50M
EPS (ttm)	-0.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	589,020
Open	0.7500
Previous Close	0.7500
Day's Range	0.7427 - 0.8070
52-Week Range	0.6150 - 1.7000
Beta	-0.05
Analysts	Buy
Price Target	2.00 (+147.83%)
Earnings Date	Nov 13, 2025

About XLO

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineere...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 22, 2021
• Employees: 64
• Stock Exchange: NASDAQ
• Ticker Symbol: XLO
• Website: https://xiliotx.com

Analyst Summary

According to one analyst, the rating for XLO stock is "Buy" and the 12-month stock price target is $2.0.

Price Target

$2.0

(147.83% upside)

Analyst Consensus: Buy